The Claim
In adults with type 2 diabetes, once-weekly exenatide reduces the overall burden of heart failure hospitalizations, including first and recurrent events, by 18% compared to control, with a hazard ratio of 0.82 (95% CI 0.68–0.99), based on a prespecified recurrent event analysis from a randomized controlled trial of 14,752 participants. The treatment does not prevent the first hospitalization but lowers the rate of rehospitalizations.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Taking a weekly diabetes shot called exenatide doesn’t stop the first heart failure hospital stay, but it does cut down on how often people end up back in the hospital for heart problems by about 18%.
See the scientific wording
Once-weekly exenatide reduces the risk of first plus recurrent hospitalizations for heart failure by 18% in adults with type 2 diabetes, with a hazard ratio of 0.82 (95% CI 0.68–0.99), based on a prespecified recurrent event analysis of 14,752 participants in a randomized controlled trial. This indicates that while exenatide does not prevent the first hospitalization, it lowers the overall burden of heart failure rehospitalizations.
What the research says
1 studyThe study tested once-weekly exenatide in people with type 2 diabetes and found it lowered the total number of heart failure hospitalizations, including repeat ones, by 18%, just as the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.